All news

Dermata Therapeutics falls 13.17% pre-market without new news

Alpha Vantage · Kalkine · · AI-summarised by FinFlash

Dermata Therapeutics (NASDAQ:DRMA) fell 13.17% pre-market to USD 0.7595, with no new company-specific announcements. The drop partly reverses a 37.19% gain on October 15 that followed positive topline results from an open-label cosmetic study of its Tome Foundational Treatment. Investors are watching for third-quarter results and any financing or listing notices, given recurring losses and the company's cash position.

Read original source

DRMA company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.